Rehabilitación oncológica en cardiotoxicidad: rompiendo paradigmas en la atención al sobreviviente de cáncer

  • Maria Fernanda Vásquez Rojas Médica, Especialista en Medicina Física y Rehabilitación, Universidad Militar Nueva Granada. Fellow en formación de Rehabilitación Oncológica. Instituto Nacional de Cancerología, Bogotá, Colombia https://orcid.org/0000-0001-9480-6395
  • Yudi Milena Rodríguez Mojica Médica, Especialista en Medicina Física y Rehabilitación, Universidad Militar Nueva Granada. Especialista en Rehabilitación Oncológica. Hospital Central de la Policía, Bogotá, Colombia. https://orcid.org/0000-0001-5947-9157
  • Miguel Mauricio Moreno Capacho Médico, Especialista en Medicina Física y Rehabilitación, Especialista en Rehabilitación Oncológica. Coordinador Grupo Área Soporte Oncológico, Instituto Nacional de Cancerología, Bogotá, Colombia. https://orcid.org/0000-0003-1045-237X
  • Gustavo Alejandro Palomino Ariza Médico, Especialista en Medicina Interna, Especialista en Cardiología. Hospital Militar Central, Bogotá, Colombia. https://orcid.org/0000-0002-9953-5659
Palabras clave: Cáncer, factores de riesgo, sobreviviente, enfermedad cardiovascular, cardiototoxicidad

Resumen

Con avances progresivos en la detección y el tratamiento del cáncer, la supervivencia ha mejorado drásticamente en las últimas décadas. El cáncer y las enfermedades cardiovasculares son las principales causas de muerte en los países de ingresos altos. Se pueden encontrar complicaciones cardiovasculares en pacientes con cáncer como resultado de la denominada ‘cardiototoxicidad’. Existe una serie de tratamientos contra el cáncer que se han asociado con diversos grados de lesión cardiovascular, los cuales pueden mostrar consecuencias cardiovasculares hasta años después de la finalización del tratamiento del cáncer. El desarrollo de disfunción cardíaca relacionada con el tratamiento del cáncer tiene un alto riesgo de morbilidad y mortalidad. La detección temprana de los factores de riesgo parece fundamental para prevenir enfermedades cardiovasculares a largo plazo. En esta revisión se analizaron los factores de riesgo de la terapia sistémica y la radioterapia como generadores de cardiototoxicidad.

Descargas

La descarga de datos todavía no está disponible.

Referencias bibliográficas

Yépez M, Jurado D, Bravo L, Bravo L. Trends on cancer incidence mortality and survival in Pasto, Colombia. 15 years experience. Colomb Medica. 2018;49(1):42-54. Disponible en: https://dx.doi.org/10.25100%2Fcm.v49i1.3616

International Agency for Research on Cancer – World Health Organization [WHO]. Cancer Today - Data visualization tools for exploring the global cancer burden in 2020 [Internet]. 2021 [citado 22 de abril de 2021]. Disponible en: http://gco.iarc.fr/today/home

Santa Mina D, Brahmbhatt P, Lopez C, Baima J, Gillis C, Trachtenberg L, et al. The Case for Prehabilitation Prior to Breast Cancer Treatment. PM&R. 2017;9(9S2):S305-S316. Disponible en: https://doi.org/10.1016/j.pmrj.2017.08.402

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-289. Disponible en: https://doi.org/10.3322/caac.21349

Pituskin E, Kirkham AA, Cox-Kennett N, Dimitry R, Dimitry J, Paterson I, et al. Rehabilitation Needs in Cancer Treatment-Related Cardiotoxicity. Semin Oncol Nurs. 2020;36(1):150986. Disponible en: https://doi.org/10.1016/j.soncn.2020.150986

Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019;139(21):e997-1012. Disponible en: https://doi.org/10.1161/CIR.0000000000000679

Minasian LM, Myrtie D, Bonnie K. Efectos cardiovasculares del tratamiento del cáncer. En: Niederhuber JE, coordinador. Abeloff - Oncología clínica. 6ª. ed. Madrid: Elsevier; 2020. p. 649-664. Disponible en: https://www.elsevier.com/books/abeloff-oncologia-clinica/niederhuber/978-84-9113-520-3

Babiker HM, McBride A, Newton M, Boehmer LM, Drucker AG, Gowan M, et al. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186-200. Disponible en: https://doi.org/10.1016/j.critrevonc.2018.03.014

Fernández AE. Chemotherapy-induced dysfunction. e-J Cardiol Pract. [Internet]. 2017 [citado 11 de mayo de 2021];14(40):marzo 17. Disponible en: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/Chemotherapy-induced-dysfunction

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-939. Disponible en: https://doi.org/10.1016/j.echo.2014.07.012

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-2801. Disponible en: https://doi.org/10.1093/eurheartj/ehw211

Virizuela JA, García AM, de Las Peñas R, Santaballa A, Andrés R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019;21(1):94-105. Disponible en: https://doi.org/10.1007/s12094-018-02017-3

Nhola LF, Villarraga HR. Fundamentos de las unidades de cardio-oncología. Rev Esp Cardiol. 2017;70(7):583-589. Disponible en: http://doi.org/10.1016/j.recesp.2017.01.025

Shakir DK, Rasul KI. Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. J Clin Med Res. 2009;1(1):8-12. Disponible en: https://doi.org/10.4021/jocmr2009.02.1225

Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med. 2014;24(7):285-295. Disponible en: https://doi.org/10.1016/j.tcm.2014.07.003

Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(2):277-281. Disponible en: https://doi.org/10.1093/annonc/mdg070

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153. Disponible en: https://doi.org/10.1186/1471-2407-7-153

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;(4):CD006243. Disponible en: https://doi.org/10.1002/14651858.cd006243.pub2

Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95(7):1592-1600. Disponible en: https://doi.org/10.1002/cncr.10854

Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138-1144. Disponible en: https://doi.org/10.1200/jco.2009.24.2024

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791. Disponible en: https://doi.org/10.1056/nejmoa1209124

Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919-1928. Disponible en: https://doi.org/10.1182/blood.2019000840

Darby SC, Ewertz M, Hall P. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med. 2013;368(26):2527. Disponible en: https://doi.org/10.1056/nejmc1304601

Cutter DJ, Darby SC, Yusuf SW. Risks of Heart Disease after Radiotherapy. Tex Heart Inst J. 2011;38(3):257-258. Disponible en: PMC31131 33

Aleman BMP, Van den Belt-Dusebout AW, De Bruin ML, Van ’t Veer MB, Baaijens MHA, De Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886. Disponible en: https://doi.org/10.1182/blood-2006-07-034405

Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. J Natl Cancer Inst. 2012;104(17):1293-1305. Disponible en: https://doi.org/10.1093/jnci/djs317

Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology. 2016;27(1):6-13. Disponible en: https://doi.org/10.1097/ede.0000000000000394

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthra-cycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Disponible en: https://doi.org/10.1186/1471-2407-10-337

Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64. Disponible en: https://doi.org/10.1186/bcr2901

Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med. 2014;24(7):285-295. Disponible en: https://dx.doi.org/10.1016%2Fj.tcm.2014.07.003

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. Disponible en: https://doi.org/10.1200/jco.2016.70.5400

Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614-622. Disponible en: https://doi.org/10.1093/annonc/mdj134

Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996;14(12):3112-3120. Disponible en: https://doi.org/10.1200/jco.1996.14.12.3112

Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1(1):10. Disponible en: https://doi.org/10.1186/2162-3619-1-10

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-2481. Disponible en: https://doi.org/10.1161/CIRCULATIONAHA.106.635144

Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of -adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-426. Disponible en: https://www.unboundmedicine.com/medline/citation/23425978/Cardioprotective_effect_of_%CE%B2_adrenoceptor_blockade_in_patients_with_breast_cancer_undergoing_chemotherapy:_follow_up_study_of_heart_failure_

Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-2262. Disponible en: https://doi.org/10.1016/j.jacc.2006.07.052

Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Mueller R-P, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):268-276. Disponible en: https://doi.org/10.1016/j.ijrobp.2011.05.054

Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012;23(5):1259-1266. Disponible en: https://doi.org/10.1093/annonc/mdr439

Brown S-A. Preventive Cardio-Oncology: The Time Has Come. Front Cardiovasc Med [Internet]. Enero 10 de 2020 [citado 7 de marzo de 2021]. Disponible en: https://doi.org/10.3389/fcvm.2019.00187

Segal R, Zwaal C, Green E, Tomasone JR, Loblaw A, Petrella T, et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017;24(4):e290-e315. Disponible en: https://dx.doi.org/10.3747%2Fco.24.3619

Patel AV, Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al. American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. Med Sci Sports Exerc. 2019;51(11):2391-2402. Disponible en: https://doi.org/10.1249/mss.0000000000002117

Matthews CE, Moore SC, Arem H, Cook MB, Trabert B, Håkansson N, et al. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. J Clin Oncol. 2020;38(7):686-697. Disponible en: https://doi.org/10.1200/jco.19.02407

Inoue-Choi M, Robien K, Lazovich D. Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiol Biomark Prev. 2013;22(5):792-802. Disponible en: https://doi.org/10.1158/1055-9965.epi-13-0054

Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical Activity and Survival After Prostate Cancer. Eur Urol. 2016;70(4):576-585. Disponible en: https://doi.org/10.1016/j.eururo.2015.12.032

Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer sur vivors: a systematic review and meta-analysis. J Cancer Sur viv. 2010;4(2):87-100. Disponible en: https://doi.org/10.1007/s11764-009-0110-5

Hayward R, Lien CY, Jensen BT, Hydock DS, Schneider CM. Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model. Pediatr Blood Cancer. 2012;59(1):149–154, . Disponible en: http://doi.org/10.1002/pbc.23392

Chen JJ, Wu PT, Middlekauff HR, Nguyen KL. Aerobic exercise in antracycline induced cardiotoxicity: a systematic review of current evidence and future directions. Am J Physiol Heart Circ Physiol. 2017;312(2):H213- 222. Disponible en: http://doi.org/10.1152/ajpheart.00646.2016

Maddocks M. Physical activity and exercise training in cancer patients. Clin Nutr ESPEN. 2020;40:1-6. Disponible en: https://doi.org/10.1016/j.clnesp.2020.09.027

Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015;65(3):167-189. Disponible en: https://doi.org/10.3322/caac.21265

Ng AH, Ngo-Huang A, Vidal M, Reyes-Garcia A, Liu DD, Williams JL, et al. Exercise Barriers and Adherence to Recommendations in Patients With Cancer. JCO Oncol Pract. 2021;17(7):e972-e981. Disponible en: http://doi.org/10.1200/OP.20.00625

Stubblefield MD. The Underutilization of Rehabilitation to Treat Physical Impairments in Breast Cancer Survivors. PM&R. 2017;9(9S2):S317-S323. Disponible en: https://doi.org/10.1016/j.pmrj.2017.05.010

Publicado
2021-09-20
Cómo citar
Vásquez Rojas, M. F., Rodríguez Mojica, Y. M., Moreno Capacho, M. M., & Palomino Ariza, G. A. (2021). Rehabilitación oncológica en cardiotoxicidad: rompiendo paradigmas en la atención al sobreviviente de cáncer. Revista Colombiana De Medicina Física Y Rehabilitación, 31(1), 58-72. https://doi.org/10.28957/rcmfr.v31n1a7
Sección
Artículos de revisión